Cadila Healthcare (Zydus Cadila) on Wednesday informed that the company has received the final approval from the US drug regulator to market Voriconazole tablets in the US market.
In its statement the company informed that it received the final approval from the US Food and Drug Administration (USFDA) to market Voriconazole Tablets in strengths of 50 mg and 200 mg. "The drug will be produced at the group’s formulations manufacturing facility at Baddi," it said here.
The estimated sales for Voriconazole Tablets which is used in the treatment of fungal infections, is USD 92.8 million, as per IMS (MAT March 2016).
The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare shares traded positive on the National Stock Exchange (NSE) at 319.85 on Wednesday, 0.69 per cent up from its previous close.